Peri-operative Cefazolin Prophylaxis at Time of Cesarean Delivery in the Obese Gravida
This study has been completed.
Sponsor:
University of Pittsburgh
Information provided by (Responsible Party):
Omar M Young, MD, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT01904500
First received: July 10, 2013
Last updated: August 15, 2014
Last verified: August 2014
| Tracking Information | ||||
|---|---|---|---|---|
| First Received Date ICMJE | July 10, 2013 | |||
| Last Updated Date | August 15, 2014 | |||
| Start Date ICMJE | August 2013 | |||
| Primary Completion Date | April 2014 (final data collection date for primary outcome measure) | |||
| Current Primary Outcome Measures ICMJE |
Plasma area under the curve (AUC) of cefazolin [ Time Frame: Within the first 8 hours after skin incision ] [ Designated as safety issue: No ] The primary aim of this study will be to evaluate the plasma area under the curve (AUC) of cefazolin in both the 2 grams and 3 grams groups. Blood samples will be obtained prior to administration of cefazolin and then 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 4 hours, 6 hours and 8 hours from administration of cefazolin |
|||
| Original Primary Outcome Measures ICMJE | Same as current | |||
| Change History | Complete list of historical versions of study NCT01904500 on ClinicalTrials.gov Archive Site | |||
| Current Secondary Outcome Measures ICMJE |
|
|||
| Original Secondary Outcome Measures ICMJE |
|
|||
| Current Other Outcome Measures ICMJE | Not Provided | |||
| Original Other Outcome Measures ICMJE | Not Provided | |||
| Descriptive Information | ||||
| Brief Title ICMJE | Peri-operative Cefazolin Prophylaxis at Time of Cesarean Delivery in the Obese Gravida | |||
| Official Title ICMJE | Peri-operative Cefazolin Prophylaxis at Time of Cesarean Delivery in the Obese Gravida | |||
| Brief Summary | Obesity has become an increasingly prevalent public health problem in the United States, reaching epidemic proportions. According to 2009 CDC epidemiologic data on obesity in the United States, 35.7% of the United States population is considered overweight or obese. Currently, on the review of the literature, over 20% of pregnancies in this country are complicated by maternal obesity. Obesity has been well demonstrated to be correlated with numerous adverse pregnancy outcomes such hypertensive disorders of pregnancy, gestational diabetes, and increased rates of operative delivery. Moreover, obesity, irrespective of pregnancy, has been demonstrated to be an independent risk factor for the development of postoperative surgical site infections. Development of such infections can have both consequential long-term medical sequelae for patients and economic impacts on the health care system at large. Cefazolin, a first generation hydrophilic cephalosporin whose clearance is exclusively mediated via the kidneys unchanged, is used as pre-operative antibiotic prophylaxis for cesarean deliveries. The current accepted standard of care is to administer 2 grams of cefazolin within 60 minutes of skin incision. Studies of drug concentrations of cephalosporins for pre-operative antibiotic prophylaxis in obese bariatric patients have shown that therapeutic concentrations may not be achieved in both tissue and plasma. Limited data exist in pregnancy. Therefore, it is the goal of this study to investigate whether obese patients presenting for cesarean delivery require an increased dosing amount of pre-operative antibiotic prophylaxis. This study will randomized women with a pre-pregnancy body mass index of 30 kg/m2 or more who are presenting for their scheduled cesarean delivery to receive either 2 grams or 3 grams of cefazolin for pre-operative antibiotic prophylaxis. By drawing blood at specific time points in the peri-operative period and extracting adipose tissue samples during cesarean delivery, this study will investigate the pharmacokinetics of cefazolin in both the plasma and tissues of the obese gravida. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase | Phase 1 | |||
| Study Design ICMJE | Allocation: Randomized Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
|||
| Condition ICMJE |
|
|||
| Intervention ICMJE | Drug: Pre-operative cefazolin | |||
| Study Arm (s) |
|
|||
| Publications * |
|
|||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Estimated Enrollment ICMJE | 26 | |||
| Completion Date | April 2014 | |||
| Primary Completion Date | April 2014 (final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
|||
| Gender | Female | |||
| Ages | 18 Years and older (Adult, Senior) | |||
| Accepts Healthy Volunteers | Yes | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT01904500 | |||
| Other Study ID Numbers ICMJE | PRO13040497 | |||
| Has Data Monitoring Committee | Not Provided | |||
| Plan to Share Data | Not Provided | |||
| IPD Description | Not Provided | |||
| Responsible Party | Omar M Young, MD, University of Pittsburgh | |||
| Study Sponsor ICMJE | University of Pittsburgh | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
|
|||
| Information Provided By | University of Pittsburgh | |||
| Verification Date | August 2014 | |||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
||||